Research programme: phytocannabinoid-based ocular therapeutics - InMed Pharmaceuticals

Drug Profile

Research programme: phytocannabinoid-based ocular therapeutics - InMed Pharmaceuticals

Alternative Names: CTI-085

Latest Information Update: 26 Mar 2015

Price : $50

At a glance

  • Originator Cannabis Technologies
  • Developer InMed Pharmaceuticals; University of Debrecen
  • Class Cannabinoids
  • Mechanism of Action Gene expression modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Glaucoma
  • Research Hypersensitivity

Most Recent Events

  • 23 Mar 2015 InMed Pharmaceuticals receives exemption from Health Canada for using phytocannabinoids for research and preclinical studies
  • 10 Mar 2015 Early research in Hypersensitivity (ocular allergies) in Hungary (unspecified route)
  • 10 Mar 2015 InMed Pharmaceuticals enters into a strategic collaboration with the University of Debrecen to develop phytocannabinoid-based therapies for the treatment of Hypersensitivity (ocular allergies)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top